791, p=004) but only increased during therapy in cirrhotic patie

791, p=0.04) but only increased during therapy in cirrhotic patients. Whilst changes in creatinine levels were similar during therapy, Talazoparib nmr higher baseline Cystatin C levels (>900 ng/ml) were linked to >20% decline in eGFR by TW12 (PPV 86%). Conclusion: At the start of treatment Cystatin C levels (>900 ng/ml) can be used to determine which patients will have significant renal dysfuntion during treatment and serum NGAL levels greater than 70 ng/ml can determine those that will require EPO support during PI containing therapy, regardless of level of fibrosis. These biomarkers

have the potential to enhance safer delivery of PI based antiviral therapy. Disclosures: Ivana Carey – Grant/Research Support: Gilead, BMS, Roche; Speaking and Teaching: BMS Kosh Agarwal – Advisory Committees or Review Panels: Gilead, Novartis, Abbott; Grant/Research Support: Roche, MSD; Speaking and Teaching: BMS, Astellas, Janssen The following people have nothing to disclose: Suman Verma Background: HCV infection is a leading contributor toward advanced liver disease, transplantation, and liver-related

deaths in New Zealand. Current low rates of treatment uptake and efficacy have had little impact on the HCV epidemic. A modeling approach was used to estimate progression of the HCV epidemic and measure Caspase inhibitor the burden of HCV-related morbidity and mortality. Methods: Age- and gender-defined cohorts were used to follow the viremic population in New Zealand, and estimate HCV incidence, prevalence, hepatic complications, and mortality. Base case assumptions were derived from the literature and country-specific data sources. The relative impact of two scenarios on HCV-related outcomes was assessed: 1) increased sustained virologic response (SVR), and 2) increased SVR and treatment with

reductions in new cases. Results: Under the base case, viremic prevalence is estimated to have peaked in 2010 (50,480 cases), declining 1% to 50,000 by 2013. In 2013, it is estimated MCE that over 70% of the infected population was born between 1955 and 1980. By 2030, the infected population is projected to decline to 39,950 cases, a 22% decrease from 2013. Compensated cirrhosis is projected to peak at 8,340 cases after 2030, a 155% increase from 2013, while decompensated cirrhosis will peak at 1,100 cases (165% increase), and cases of hepatocellular carcinoma increase over 200%, peaking at 500 cases. Under Scenario 1, SVR and treatment eligibility rates increase to 90% in 2016. Compared to the base case, there was an 8% reduction in prevalent cases, and a 13% reduction in liver-related deaths by 2030. Liver cancer and decompensated cirrhosis cases decreased 9% and 12%, respectively, as compared to the base case in 2030. Under Scenario 2, the same increases in SVR and treatment eligibility were modeled, with increases in the annual treated population through 2020 when 4,040 cases were treated as compared to 900 treated cases in 2013.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>